Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 546Terminated 180Recruiting 134Active not recruiting 94Unknown 63Not yet recruiting 33Withdrawn 27No longer available 15Approved for marketing 6Available 5Suspended 3Enrolling by invitation 3

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Neoplasms 18Breast Neoplasms 9Prostatic Neoplasms 8Melanoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Solid Tumors 3Multiple Myeloma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Mesothelioma 2Lymphoma, T-Cell 2Liver Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × Multiple Myeloma × Clear all
NCT06663046 2026-05-07

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Wondercel Biotech (ShenZhen)

Phase EARLY_PHASE1 Suspended
30 enrolled
Plasma cell

Multiple Myeloma

NCT04505813 2024-01-16

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

NexImmune Inc.

Phase 1/2 Suspended
9 enrolled
Plasma cell

Multiple Myeloma

NCT03752541 2022-05-20

Efficacy and Safety Evaluation of BCMA-UCART

Bioray Laboratories

Phase NA Suspended
20 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡